Biote Corp. (NASDAQ: BTMD), a leader in personalized hormone optimization and therapeutic wellness, has announced a binding term sheet with Dr. Gary S. Donovitz, Biote’s founder and stockholder, to settle…
United Therapeutics Corporation (Nasdaq: UTHR) has initiated legal action against the United States Food and Drug Administration (FDA), as announced today. The litigation centers on United Therapeutics’ claim that the…
FDA Clears Xolair as Sole Treatment for Food Allergies in Children and Adults Genentech, a member of the Roche Group, disclosed today that the U.S. Food and Drug Administration (FDA)…
TAGRISSO® and Chemotherapy Combo Approved for EGFR-Mutated Lung Cancer AstraZeneca’s TAGRISSO® (osimertinib) combined with chemotherapy has secured approval in the US for treating adult patients with locally advanced or metastatic…
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and its parent company, Otsuka Pharmaceutical Co., Ltd. (Otsuka), have disclosed the topline findings from the phase 3 clinical trial of AVP-786 aimed…
Medpace Holdings, Inc. (Nasdaq: MEDP) has released its financial results for the fourth quarter and full year ending December 31, 2023. Fourth Quarter 2023 Financial Highlights: Full Year 2023 Financial…
Following our previous update on January 5, 2024, we are delighted to share the latest advancements with you. A Phase I dose-ranging clinical trial investigating DFP-14927 in patients with solid…
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs within virology and immunology, has released its financial results for the fiscal first quarter ending December…
Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to pioneering transformative medicines for neurological diseases, has officially granted inducement awards to five new employees. The Compensation Committee of the Board of…
For Exclusive Distribution to GB Trade and Medical Media REZZAYO® (rezafungin) is approved for treating invasive candidiasis in adults. Adherence to official guidelines regarding the appropriate use of antifungal agents…
Takeda’s Chief Financial Officer Costa Saroukos Announces Departure; Milano Furuta to Assume Role Effective April 1, 2024 TOKYO, Japan — In an announcement today, Takeda disclosed that Costa Saroukos, the…
Atara Biotherapeutics and Pierre Fabre Laboratories Publish Data from Phase 3 ALLELE Tab-cel® Trial in The Lancet Oncology” Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, and Pierre…
